Drugs / Rezvilutamide
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 210 trials | ||||||
| Phase 2 | NCT07795177 | Oct 2026 → Apr 2028 expected | prostate carcinoma | Anhui Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07711314 | Jul 2026 → May 2027 expected | cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT07490210 | May 2026 → May 2032 expected | metastatic prostate carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06348264 | Oct 2024 → Mar 2029 expected | salivary duct carcinoma | Peking University First Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06505278 | Aug 2024 → Mar 2025 overdue | prostate cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06387056 | Apr 2024 → Apr 2026 overdue | metastatic prostate carcinoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06134271 | Nov 2023 → Apr 2025 | prostate carcinoma | Jianbin Bi | Unknown | No outcome recorded |
| Phase 2 | NCT06305832 | Sep 2023 → Mar 2028 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT05753566 | Mar 2023 → Mar 2027 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT05406999 | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT07241416 | Dec 2025 → Mar 2027 expected | prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05956639 | Jun 2023 → Dec 2025 overdue | metastatic prostate carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT03520478 | May 2018 → Apr 2023 | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT07444983 | Feb 2026 → Feb 2027 expected | prostate adenocarcinoma | Fujian Medical University Union Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07112209 | Nov 2023 → Jun 2027 expected | metastatic prostate carcinoma | Zhujiang Hospital | Enrolling by invitation | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 0 | NCT07389174 Background | Feb 2026 → Jan 2027 expected | prostate adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07407283 Background | Apr 2026 → Nov 2027 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07268794 Background | Nov 2025 → Apr 2027 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06832774 Background | Aug 2025 → Dec 2027 expected | metastatic prostate carcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06992232 Background | Aug 2024 → Jul 2027 expected | metastatic prostate carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 3 | NCT07611110 Comparator | May 2026 → Feb 2029 expected | prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05983783 Comparator | Aug 2023 → Dec 2025 overdue | metastatic prostate carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT06350825 Comparator | Jan 2016 → Dec 2027 expected | metastatic prostate carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rezvilutamide | “This regimen consists of Androgen Deprivation Therapy (ADT) (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix) combined with an oral Androgen Receptor (AR) inhibitor...” NCT07389174 ↗22“Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a...” PMID 36075260 ↗ Sep 2022 “Patients received ADT plus second-generation ARi (enzalutamide, apalutamide, darolutamide or rezvilutamide) for 2 years.” NCT06992232 ↗ “Triplet or doublet therapy (ie. docetaxel/abiraterone, apalutamide，Rezvilutamide，darolutamide，enzalutamide)” NCT06350825 ↗ “6-month course of Rezvilutamide and ADT + chemotherapy” NCT05956639 ↗ |
| Known as | REZ | “The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive...” PMID 39690158 ↗ Dec 2024 |
| Known as | SHR3680 | “Rezvilutamide (SHR3680), a novel androgen receptor inhibitor independently developed by a Chinese pharmaceutical company” NCT07490210 ↗ |
| Action | Inhibit | “Rezvilutamide, a novel androgen-receptor inhibitor with low blood-brain barrier penetration” PMID 36075260 ↗ Sep 2022 |
| Route | Oral | “240 mg (80 mg × 3 tablets) once daily orally” NCT05406999 ↗ |
| Target | AR | “a potent new-generation oral androgen receptor (AR) inhibitor” NCT07444983 ↗ |